Foghorn Therapeutics Inc (FHTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $124.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Foghorn Therapeutics Inc (FHTX) Financials: Revenue, Profit and Cash Flow
Foghorn Therapeutics reported revenue of $30.91M for the fiscal year ended Dec 31, 2025, up 36.8% from the year before. That year, net income was -$74.28M with a net margin of -240.3%, operating cash flow was -$86.10M and free cash flow was -$86.15M. The quarter ended Sep 30, 2026 had revenue of $83.54M and net income of $58.15M.
Revenue and Margins
Over the 5 years to Dec 2025, revenue grew from $430.00K, a compound annual rate of 135.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $30.91M | +36.8% | 100.0% | -279.5% | -240.3% |
| Dec 2024 | $22.60M | -33.8% | 100.0% | -454.3% | -383.2% |
| Dec 2023 | $34.16M | +77.6% | 100.0% | -315.9% | -288.2% |
| Dec 2022 | $19.23M | +1357.8% | 100.0% | -609.2% | -566.3% |
| Dec 2021 | $1.32M | +206.7% | 100.0% | -7637.1% | -7681.6% |
| Dec 2020 | $430.00K | N/A | 100.0% | -15937.4% | -16000.0% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M | $430.00K | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $379.00K |
| Gross profit | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M | $430.00K | $0 | -$379.00K |
| Research and development | $85.47M | $94.53M | $109.69M | $105.62M | $80.33M | $57.72M | $44.36M | $21.23M |
| Operating income | -$86.39M | -$102.68M | -$107.91M | -$117.14M | -$100.73M | -$68.53M | -$51.08M | -$26.05M |
| Net income | -$74.28M | -$86.62M | -$98.43M | -$108.88M | -$101.32M | -$68.80M | -$51.13M | -$26.34M |
| EBITDA | -$81.62M | -$100.01M | -$104.28M | -$112.53M | -$94.83M | -$66.27M | -$49.90M | -$25.59M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.54M | $16.07M | $3.27M | $9.25M | $8.15M | $7.56M | $5.95M | $2.86M | $7.81M | $6.89M | $5.05M | $5.77M |
| Gross profit | $83.54M | $16.07M | $3.27M | $9.25M | $8.15M | $7.56M | $5.95M | $2.86M | $7.81M | $6.89M | $5.05M | $5.77M |
| Operating income | $56.64M | -$8.80M | -$21.57M | -$23.88M | -$18.50M | -$21.10M | -$22.91M | -$24.00M | -$23.85M | -$26.63M | -$28.19M | -$25.46M |
| Net income | $58.15M | -$7.19M | -$19.88M | -$21.66M | -$15.85M | -$17.94M | -$18.83M | -$19.50M | -$19.12M | -$22.98M | -$25.02M | -$24.11M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $923.00K by $79.95M. Shareholder equity was negative, at -$108.50M, as total liabilities of $306.60M exceeded total assets of $198.10M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $198.10M | $283.98M | $285.92M | $404.88M | $519.77M | $255.59M | $22.34M | $43.06M |
| Current assets | $163.24M | $249.60M | $240.18M | $351.40M | $459.56M | $190.69M | $16.89M | $40.40M |
| Cash and equivalents | $80.88M | $55.45M | $80.34M | $52.21M | $101.14M | $92.80M | $14.98M | $40.02M |
| Total liabilities | $306.60M | $329.51M | $363.11M | $404.77M | $422.90M | $109.41M | $23.81M | $82.33M |
| Short-term debt | $923.00K | $9.07M | $8.52M | $5.97M | $6.99M | $3.98M | $4.15M | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $19.65M | $10.96M | $7.03M |
| Shareholder equity | -$108.50M | -$45.53M | -$77.19M | $112.00K | $96.87M | $146.19M | -$88.02M | -$39.27M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $190.95M | $203.39M | $222.17M | $198.10M | $204.96M | $226.24M | $258.69M | $283.98M | $308.37M | $328.58M | $255.00M | $285.92M |
| Total liabilities | $205.04M | $284.43M | $298.57M | $306.60M | $294.62M | $302.89M | $320.34M | $329.51M | $336.66M | $342.91M | $352.49M | $363.11M |
| Cash and equivalents | $80.30M | $68.08M | $87.66M | $80.88M | $89.33M | $72.57M | $61.03M | $55.45M | $57.68M | $138.95M | $79.25M | $80.34M |
| Shareholder equity | -$14.08M | -$81.04M | -$76.41M | -$108.50M | -$89.66M | -$76.66M | -$61.65M | -$45.53M | -$28.29M | -$14.32M | -$97.49M | -$77.19M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$86.10M | -$100.41M | -$118.11M | $193.61M | -$50.25M | -$31.29M | -$46.34M | -$22.65M |
| Capital expenditures | $50.00K | $906.00K | $1.22M | $1.21M | $3.31M | $16.18M | $968.00K | $1.54M |
| Free cash flow | -$86.15M | -$101.31M | -$119.33M | $192.40M | -$53.56M | -$47.47M | -$47.30M | -$24.19M |
| Share repurchases | $0 | $585.00K | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $112.04M | -$29.90M | $144.45M | -$244.32M | $36.17M | -$108.91M | -$964.00K | -$1.54M |
| Financing cash flow | $1.02M | $105.43M | $1.78M | $1.76M | $22.42M | $217.47M | $23.97M | $51.77M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.24M | -$17.84M | -$25.27M | -$22.27M | -$18.86M | -$21.00M | -$23.97M | -$24.52M | -$21.00M | -$25.54M | -$29.34M | -$27.54M |
| Capital expenditures | $7.00K | $50.00K | $0 | $0 | $0 | $22.00K | $28.00K | $479.00K | $309.00K | $17.00K | $101.00K | $37.00K |
| Free cash flow | -$18.25M | -$17.89M | -$25.27M | -$22.27M | -$18.86M | -$21.02M | -$24.00M | -$25.00M | -$21.31M | -$25.55M | -$29.45M | -$27.58M |
Frequently Asked Questions About FHTX
What is Foghorn Therapeutics' annual revenue?
Foghorn Therapeutics reported revenue of $30.91M for the fiscal year ended Dec 31, 2025.
How fast is Foghorn Therapeutics' revenue growing?
Revenue was up 36.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.1%.
Is Foghorn Therapeutics profitable?
No. Foghorn Therapeutics reported net income of -$74.28M for the fiscal year ended Dec 31, 2025, with a net margin of -240.3%.
How much free cash flow does FHTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$86.10M minus capital expenditures of $50.00K produced free cash flow of -$86.15M.
How much debt does Foghorn Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $923.00K and cash and equivalents of $80.88M.
FHTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors